LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
- Based on the successfully completed single-dose part of the phase I clinical trial in Korean population carried out by JW Pharmaceutical, LEO Pharma files IND application to the FDA for study of JW1601/LP0190 in US set to start in 2020.
Ballerup, Denmark, and Seoul, Korea, August 27th, 2019: LEO Pharma, a global leader in medical dermatology, and Korean JW Pharmaceutical today announced that LEO Pharma has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a pharmacokinetics study in the US.
The filing is based on the two companies’ ongoing collaboration on the development of JW1601/LP0190, an oral treatment for atopic dermatitis for which JW Pharmaceutical out-licensed their investigatory drug to LEO Pharma in August 2018. JW Pharmaceutical has since January this year conducted phase 1 clinical trial consisting of a single dose and repeated dose studies in healthy adults. Recently the single dose phase for Koreans was successfully completed with acceptable safety and tolerability observed up to the highest dose, 5th cohort. Based on this trial LEO Pharma has now filed a protocol for a pharmacokinetics study in US – a small clinical trial with healthy volunteers to further evaluate the pharmacokinetics of JW016/LP0190.
“We are excited to see the progress of our collaboration with JW Pharmaceuticals that is now enabling us to file the IND application to the FDA and take the next step towards making an oral treatment for atopic dermatitis available. The unmet needs in this disease area are huge and an oral treatment will add substantially to the treatment options to the benefit of the many people living with this disease”, says Kim Kjoeller, Executive Vice President, Global Research & Development at LEO Pharma.
S.Y Lee, Senior Executive Vice President, Chief of Corporate Development Division said, “As the single-dose study for Koreans has been completed smoothly, LEO Pharma was able to apply for this study plan in US.” He also added that “JW Pharmaceutical will further strengthen our partnership with LEO Pharma in the future and develop JW1601 as a new drug for treatment of atopic dermatitis that will play a pivotal role in the global market.”
JW1601 is a H4R antagonist expected to have anti-pruritic and anti-inflammatory effect in atopic dermatitis. The new drug candidate is developed as an oral treatment, a more convenient route of administration with the potential to improve the compliance for the patient.
Contacts
Contact:
LEO Pharma
Henrik Kyndlev
+45 3140 6180
hdtdk@leo-pharma.com
US inquiries
LEO Pharma US
Rhonda Sciarra
+1 973 637 8019
+1 862 337 0675
rasus@leo-pharma.com
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, visit www.leo-pharma.com or follow us on LinkedIn: www.linkedin.com/company/leo-pharma
About JW PHARMACEUTICAL CORPORATION
JW Pharmaceutical Corporation has been leading Korean medicine and medical supplies market over its 70 years of history. The company focuses on the field of research and development of anti-cancer drug and etc.; manufacture and sales of hospital fluid, antibiotic and other ethical pharmaceuticals.
JW Pharmaceutical Corporation was founded in 1945 and is listed on the Korea Exchange Market under the symbol "001060 ".
More information is available at http://www.jw-pharma.co.kr/pharma/en/main.jsp.
ABOUT JW1601
JW1601 is an orally available histamine H4 receptor inverse agonist with anti-pruritic and anti-inflammatory dual effect. It shows anti-chemotactic activity in eosinophil shape change and therapeutic effect in spontaneous NC/Nga AD model. JW1601 is currently conducting pre-clinical toxicity study and looking for phase 1 IND submission in 2018 in Korea. JW1601 is an investigational compound that is not approved for any use in any country.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development16.12.2020 12:15:37 CET | Press release
Ballerup, December 16, 2020 – LEO Pharma A/S today announced that Jörg Möller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee. A medical doctor and Ph.D. by training, Jörg Möller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with exte
LEO Pharma completes sale of portfolio of four products to Cheplapharm15.12.2020 13:20:01 CET | Press release
BALLERUP, Denmark, December 15, 2020 – Today, LEO Pharma A/S announced that the sale of a portfolio of four non-core products to Cheplapharm for approximately EUR 300 million has been complet-ed. The agreement was announced on August 31, 2020.
LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day28.10.2020 08:05:00 CET | Press release
BALLERUP, Denmark, October 28, 2020 - LEO Pharma A/S today marked World Psoriasis Day by launching a series of videos featuring patients that outline the everyday challenges of living with psoriasis. The #everydaypsoriasis videos give personal perspectives on the challenges of living with psoriasis. To accompany the patient videos, LEO Pharma staff from around the world filmed a manifesto during COVID home-working restrictions, outlining their everyday commitment to supporting patients with psoriasis: WATCH OUR MANIFESTO VIDEO HERE The #everydaypsoriasis campaign video. More information can be found at www.everydaypsoriasis.com The LEO Pharma campaign is in support of the annual International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. This annual awareness day is dedicated to people living with psoriasis or psoriatic arthritis and is aimed at spreading information and raising the profile of these debilitating diseases. October 2020 marks the second year of a three
LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy23.9.2020 10:00:25 CEST | Press release
Ballerup, September 23, 2020 – LEO Pharma A/S today announced that Becki Morison will join the Global Leadership Team as Executive Vice President, Global Therapeutic & Value Strategy, effective October 1.
LEO Pharma sells portfolio of four products to Cheplapharm31.8.2020 12:34:26 CEST | Press release
- Sale of four products for EUR 300 million - Important milestone in LEO Pharma’s ambitious 2030 strategy with increased focus on new innovative solutions for medical dermatology - Transaction expected to close December 2020
LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications18.8.2020 12:02:29 CEST | Press release
Ballerup, August 18, 2020 – LEO Pharma A/S today announced that Dennis Schmidt Pedersen will join the executive leadership team as Executive Vice President Global People & Communications, effective September 1, 2020.
LEO Pharma announces U.S. Food and Drug Administration Fast Track designation for delgocitinib cream for the treatment of adults with moderate-to-severe chronic hand eczema4.8.2020 14:05:39 CEST | Press release
The purpose of the Fast Track process is to get important potential new drugs to patients earlier (1)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom